How much does a box of domestic regorafenib cost?

Regorafenib (Regorafenib) is an oral multikinase inhibitor widely used to treat a variety of advanced cancers. It exerts anti-cancer effects by inhibiting a variety of intracellular and cell surface protein kinases, interfering with tumor angiogenesis, tumor cell proliferation, and maintenance of the tumor microenvironment.

Regorafenib has now been launched in the domestic market and has been included in the medical insurance system. Patients can easily purchase it directly in China, with a price range of approximately RMB 4,000 to RMB 5,000. If you need more detailed price information and medical insurance reimbursement details, please consult your local hospital or pharmacy directly. In addition, there are both original drugs and generic drugs available in overseas markets. The price of original research drugs produced in Türkiye is moderate, only more than one thousand yuan. At the same time, generic drugs are also sold in Laos, India, Bangladesh and other places, and the prices are more affordable, ranging from a few hundred yuan to more than a thousand yuan. It is worth noting that the main pharmaceutical ingredients of these original drugs and generic drugs are highly similar.

Regorafenib is approved to treat patients with metastatic colorectal cancer who have progressed despite standard therapies, such as chemotherapy, anti-EGFR therapy, and anti-VEGF therapy. Its multi-target mechanism can effectively delay disease progression and provides a new treatment option. Regorafenib is an effective treatment for patients with advanced or metastatic gastrointestinal stromal tumors after failure of imatinib and sunitinib. GIST is a rare but aggressive gastrointestinal tumor. Regorafenib can control the disease and prolong patient survival by inhibiting multiple kinases related to tumor growth. Regofenib is also used in patients with hepatocellular carcinoma whose disease has progressed despite treatment with sorafenib. As a major primary liver cancer, treatment options for HCC are relatively limited, and regorafenib provides patients with new hope through its multi-target inhibitory effect.

Regorafenib by inhibiting multiple kinases involved in tumor angiogenesis and tumor cell proliferation, including VEGFR1-3, TIE2, RAF-1 , BRAF, KIT and RET, etc., reduce the blood supply of tumors and inhibit the proliferation and survival of tumor cells. This multi-target mechanism of action enables it to demonstrate a wide range of efficacy in the treatment of different types of cancer.

Regorafenib , as a multi-target kinase inhibitor, provides a variety of new treatment options for patients with advanced cancer. Its wide range of indications and effective anti-cancer mechanism make it of great significance in clinical application. Patients should be closely monitored while taking the medication and maintain communication with their doctor to optimize treatment effects and manage side effects.